Clinical Trial: A Study Evaluating the Pharmacokinetics, Safety, and Efficacy of Cevostamab in Chinese Participants With Relapsed or Refractory Multiple Myeloma

U.S., April 19 -- ClinicalTrials.gov registry received information related to the study (NCT06934044) titled 'A Study Evaluating the Pharmacokinetics, Safety, and Efficacy of Cevostamab in Chinese Participants With Relapsed or Refractory Multiple Myeloma' on April 09.

Brief Summary: This study will evaluate the pharmacokinetics (PK), safety, and efficacy of cevostamab in participants with relapsed or refractory (R/R) multiple myeloma (MM).

Study Start Date: May 09

Study Type: INTERVENTIONAL

Condition: Multiple Myeloma

Intervention: DRUG: Cevostamab

Cevostamab will be administered intravenously on a 21-day cycle.

DRUG: Tocilizumab

Tocilizumab will be administered for the treatment of cytokine release syndrome (CRS) when necessary....